2018 WGND Annual Meeting

October 24, 2018 | The Hague, The Netherlands
Overview

The Stop TB Partnership Working Group on New Drugs’ Annual Meeting has proven valuable as a neutral forum to bring together those working in development to get a full understanding of the progress, challenges, and critical issues to developing TB treatment.

Speakers
Melvin Spigelman
TB Alliance, WGND
Barbara Laughon
NIH/NIAID, WGND
Zaid Tanvir
TB Alliance, WGND
Irina Usherenko
Working Group on New TB Drugs
Michael Hoelscher
EDCTP/University of Munich
Joel Lilievre
GSK
Jeffrey Hafkin
Otsuka
Morounfolu Olugbosi
TB Alliance
Young Lag Cho
LegoChem Biosciences, Inc.
Emilyne Blattes
Innovative Medicines for TB
Susan Dorman
Tuberculosis Trials Consortium
Robert Wallis
The Aurum Institute
Gavin Churchyard
AIDS Clinical Trials Group
Tine DeMarez
Janssen
Meeting Recap

The 2018 WGND Annual Meeting and Reception took place on Wednesday, October 24th from 16:00 to 20:00 CET in the Studio Room at The Museon. The meeting occurred in conjunction with the 2018 Union World Conference on Lung Health in The Hague, The Netherlands. During the meeting, updates were provided on the most recent advances in the Global TB Drug Pipeline, discussion of pressing issues facing the TB drug R&D community, and other important news in TB drug development. 

 

  • From the Working Group on New Drugs
    WGND Updates
    Zaid Tanvir
    Irina Usherenko
    https://www.newtbdrugs.org/sites/default/files/meetings/files/01_WGND_Tanvir%20%26%20Usherenko.pdf
    TB Drug Development Year-in-Review
    Barbara Laughon
    https://www.newtbdrugs.org/sites/default/files/meetings/files/02_Laughon.2018.TB%20Drug%20Development%20Year%20in%20Review.pdf
  • Early Development
    LM University of Munich
    Michael Hoelscher
    https://www.newtbdrugs.org/sites/default/files/meetings/files/03_BTZ%20STZ%20WGND%202018.pdf
    GlaxoSmithKline
    Joel Lilievre
    Sequella (update presented by WGND)
    Barbara Laughon
    https://www.newtbdrugs.org/sites/default/files/meetings/files/13_Sutezolid%20Update%20for%20WGND%202018-%20The%20Hague.pdf
  • Multi-Stage Development
    Otsuka Pharmaceuticals
    Jeffrey Hafkin
    https://www.newtbdrugs.org/sites/default/files/meetings/files/05_Otsuka_WGND_2018.pdf
    TB Alliance
    Morounfolu Olugbosi
    https://www.newtbdrugs.org/sites/default/files/meetings/files/06_WGND%20Presentation_The%20Union_24Oct%202018%20v5.1%20FINAL.pdf
  • Mid-Stage Development
    LegoChem Biosciences, Inc.
    Young Lag Cho
    https://www.newtbdrugs.org/sites/default/files/meetings/files/07_WGND%20presentation-LegoChem%20Bio.pdf
    Innovative Medicines for TB
    Emilyne Blattes
    CDC / Tuberculosis Trials Consortium
    Susan Dorman
    https://www.newtbdrugs.org/sites/default/files/meetings/files/09_TBTC%20Update%20for%20WGND_24Oct2018.pdf
    The Aurum Institute
    Robert Wallis
    https://www.newtbdrugs.org/sites/default/files/meetings/files/10_Wallis%20TB%20HDT%20WGND%202018.pdf
    AIDS Clinical Trial Group
    Gavin Churchyard
    https://www.newtbdrugs.org/sites/default/files/meetings/files/11_ACTG%20overview-24.10.18.pdf
  • Late-Stage Development
    Janssen
    Tine DeMarez
    https://www.newtbdrugs.org/sites/default/files/meetings/files/12_WGND_24Oct18.pdf
Related Links
Global TB Drug Pipeline